Cavernous Hemangioma of the Retina

Cavernous Hemangioma of the Retina is a rare, benign (non-cancerous) vascular hamartoma that forms clusters of thin-walled, blood-filled sacs within the retina. These grape-like clusters lie just beneath the light-sensing cells at the back of the eye and usually grow very slowly. Most people with retinal cavernous hemangiomas never notice any problems, because these lesions often do not leak or press on important parts of the eye NCBIWebEye. However, when they occur near the central vision area (macula), bleed into the jelly-like vitreous, or trigger scar tissue, they can cause vision changes.

A cavernous hemangioma of the retina is a rare, benign vascular malformation consisting of clusters of thin‐walled, blood‐filled “caverns” within the inner retinal layers. Under the microscope, these lesions appear as large, interconnected vascular spaces lined by a single layer of endothelium, often with overlying fibroglial tissue from previous minor hemorrhages Retina Today. Ophthalmoscopically, they resemble a “bunch of concord grapes” along a retinal vein, typically discovered incidentally because most remain small and asymptomatic Retina Today. Familial forms occur in an autosomal dominant pattern (CCM1/KRIT1, CCM2/MGC4607, CCM3/PDCD10 mutations), and bilateral cases strongly correlate with family history, warranting genetic testing and brain MRI to screen for cerebral cavernous malformations Retina TodayScienceDirect.

Types

Retinal cavernous hemangiomas can be divided into two main types based on their context and presentation:

1. Isolated (Sporadic) Lesions

   • These occur by themselves in one eye without any associated systemic condition.

   • They usually appear as a single cluster of vascular sacs.

   • No family history or other organ involvement is present WebEye.

2. Syndromic (Familial) Lesions

   • These occur in people with inherited vessel-growth disorders, most commonly cavernous malformation syndromes of the brain and spinal cord.

   • They may affect both eyes and carry a higher risk of related lesions elsewhere in the body.

   • Often linked to mutations in the CCM1, CCM2, or CCM3 genes that regulate blood-vessel development PMC.

Causes

Although the exact triggers for retinal cavernous hemangioma are not fully understood, most cases arise from congenital vascular malformations. Below are twenty factors thought to play a role:

1. Congenital Malformation
   Abnormal clustering of blood vessels develops in the retina before birth, leading to grape-like vascular sacs.

2. Genetic Mutations (CCM Genes)
   Mutations in CCM1 (KRIT1), CCM2 (MGC4607), or CCM3 (PDCD10) can disrupt normal vessel walls, causing cavernous malformations in the eye and brain PMC.

3. Familial Inheritance
   A parent’s mutation passes down, increasing the chance of vascular malformations in multiple organs, including the retina.

4. Sporadic Mutation
   A random genetic change not inherited from parents can still produce a cavernous hemangioma in one eye.

5. Von Hippel–Lindau Syndrome
   An inherited disorder with various blood-vessel tumors, sometimes including retinal hemangiomas.

6. Sturge-Weber Syndrome
   A neurocutaneous condition with facial port-wine stains and abnormal blood vessels in the brain and eye.

7. Trauma-Induced Vascular Injury
   Severe eye injury can damage vessel walls, possibly triggering abnormal vessel growth as a repair response.

8. Chronic Inflammation
   Long-term inflammation in the eye (e.g., uveitis) can weaken vessel walls and promote malformation.

9. Radiation Exposure
   Radiation near the eye (e.g., from cancer treatment) can damage blood vessels, leading to malformations over time.

10. Hormonal Changes
    Fluctuations in hormones (for example during puberty or pregnancy) may influence vessel growth and stability.

11. Pregnancy
    Increased blood volume and vessel dilation during pregnancy can unmask or enlarge existing malformations.

12. Hypertension (High Blood Pressure)
    Chronic high pressure in the blood vessels can stress vessel walls, contributing to malformation.

13. Hyperlipidemia (High Blood Fat Levels)
    Fat deposits in vessel walls may weaken their structure, promoting abnormal growth.

14. Diabetes Mellitus
    Long-term high blood sugar damages small vessels, potentially triggering malformations as cells attempt to repair.

15. Smoking
    Tobacco toxins harm blood vessels and can aggravate congenital malformations.

16. Autoimmune Disorders
    Conditions like systemic lupus erythematosus can inflame vessel walls and encourage abnormal clustering.

17. Infectious Agents
    Eye infections (e.g., toxoplasmosis) can scar vessels, which then remodel improperly.

18. Retinal Hypoxia (Low Oxygen)
    Low oxygen in retinal tissue may trigger new vessel formation, sometimes in an uncontrolled way.

19. Hypercoagulable States
    Blood-clotting disorders can thicken vessel linings, leading to focal expansions.

20. Toxic Chemical Exposure
    Certain chemicals (like heavy metals) can damage endothelial cells, causing them to grow abnormally.

Symptoms

Most retinal cavernous hemangiomas do not cause symptoms. When problems arise, they include:

1. Asymptomatic
   No vision changes or discomfort; lesion is found by chance during an eye exam Illinois Retina Associates.

2. Blurry Vision
   Vision becomes less sharp if the lesion interferes with the macula.

3. Floaters
   Small dark spots or lines drifting in vision, often due to minor leakage into the vitreous.

4. Vitreous Hemorrhage
   Bleeding into the gel that fills the eye, causing sudden dark spots or “cloudy” vision.

5. Visual Field Defect
   Missing areas in side or central vision if the lesion blocks a part of the retina.

6. Metamorphopsia
   Straight lines appear wavy when the macula is affected.

7. Photopsia
   Flashes of light when vessels tug on the retina.

8. Scotoma
   A blind spot in vision, corresponding to lesion location.

9. Micropsia/Macropsia
   Objects appear smaller (micropsia) or larger (macropsia) than they are.

10. Eye Pain
    Mild discomfort if the lesion causes inflammation.

11. Red Eye
    Surface redness when low-grade bleeding irritates the eye.

12. Photophobia
    Light sensitivity due to vitreous changes.

13. Reduced Color Vision
    Colors look faded if macular function is impaired.

14. Contrast Sensitivity Loss
    Difficulty telling shades of gray apart.

15. Tractional Retinal Changes
    Scar tissue pulls on the retina, subtly distorting vision.

Diagnostic Tests

A combination of clinical and technical tests helps confirm retinal cavernous hemangioma:

Physical Exam

1. Visual Acuity Test
   Measures clarity of vision using a letter chart.

2. Pupillary Light Reflex
   Checks how pupils respond to light.

3. Intraocular Pressure Measurement
   Uses a tonometer to rule out glaucoma.

4. External Eye Inspection
   Examines eyelids, lashes, and eye alignment.

5. Confrontation Visual Field
   Screens for field defects.

Manual (Bedside) Tests

6. Slit-Lamp Examination
   Magnified view of front and back eye structures.

7. Indirect Ophthalmoscopy
   Wide-field view of the retina using a head-mounted lens.

8. Amsler Grid Test
   Detects macular distortion (wavy lines).

9. Color Vision Testing
   Assesses red–green color discrimination.

10. Fundus Photography
    Captures detailed still images of the retina.

Lab & Pathological Tests

11. Genetic Testing
    Screens for CCM gene mutations in familial cases PMC.

12. Complete Blood Count (CBC)
    Rules out bleeding disorders.

13. Coagulation Profile
    Assesses clotting function.

14. Inflammatory Markers (CRP, ESR)
    Checks for active inflammation.

15. Blood Glucose & Lipid Panel
    Screens for diabetes and hyperlipidemia.

Electrodiagnostic Tests

16. Electroretinography (ERG)
    Measures electrical responses of retinal cells to light.

17. Visual Evoked Potentials (VEP)
    Records brain responses to visual stimuli, checking optic pathway.

18. Electro-oculography (EOG)
    Monitors electrical potential changes across the eye surface.

Imaging Tests

19. Fluorescein Angiography (FA)
    Dye highlights blood flow; cavernous lesions fill slowly without leakage Illinois Retina Associates.

20. Optical Coherence Tomography (OCT)
    Cross-sectional retinal images show lesion depth and any associated edema.

21. OCT Angiography (OCTA)
    Non-invasive mapping of blood vessels without dye.

22. B-Scan Ultrasound
    Sound waves reveal lesion size and firm edges.

23. Indocyanine Green Angiography
    Deeper choroidal vessel imaging with infrared dye.

24. Magnetic Resonance Imaging (MRI)
    Detects any related brain cavernous malformations.

25. Computed Tomography (CT)
    Rarely used but can reveal calcifications.

26. Wide-Field Fundus Imaging
    Captures panorama of peripheral retina.

27. Fundus Autofluorescence
    Shows metabolic activity around the lesion.

28. Ultrawide OCT
    Larger-field OCT for peripheral lesions.

Non-Pharmacological Treatments

1. Observation (Conservative Management): Small, asymptomatic lesions without hemorrhage are monitored with periodic eye exams to watch for changes in size or vision Retina Today.

2. Regular Ophthalmic Monitoring: Scheduled fundus photography and optical coherence tomography (OCT) every 6–12 months detect subtle growth or secondary macular changes Retina Today.

3. Fluorescein Angiography (FA): Baseline and follow-up FA confirm the characteristic slow dye filling (“fluorescein-erythrocyte interface”) and rule out leakage Retina Today.

4. Pars Plana Vitrectomy: For non-resolving vitreous hemorrhage, vitrectomy clears blood and preserves vision by restoring media clarity Retina Today.

5. Epiretinal Membrane Peeling: When macular fibrosis develops, peeling the preretinal membrane can improve macular anatomy and vision Retina Today.

6. Laser Photocoagulation: Focal argon laser applied to small, peripheral lesions reduces blood flow within the hemangioma, promoting sclerosis Retina Today.

7. Photodynamic Therapy (PDT): Intravenous verteporfin followed by low-intensity laser selectively occludes vascular malformations with minimal collateral damage Retina Today.

8. Cryotherapy: Freezing anterior, peripheral lesions induces endothelial damage and vessel closure, used when laser or PDT is impractical Retina Today.

9. Plaque Brachytherapy: Ruthenium-106 or iodine-125 plaque applied episclerally delivers localized radiation, effective for medium-to-large tumors Retina Today.

10. External Beam Radiotherapy (EBRT): Low-dose EBRT treats large or juxtapapillary lesions refractory to other modalities Retina Today.

11. Transpupillary Thermotherapy (TTT): Infrared laser heats the lesion to induce thrombosis, an option for moderately sized, posterior tumors Retina Today.

12. Internal Tumor Resection: Via pars plana vitrectomy, direct surgical excision of bulky hemangiomas in vision-threatening locations Retina Today.

13. Subretinal Fluid Drainage: When exudation causes subretinal fluid, surgical drainage can flatten the retina and improve vision Retina Today.

14. Ocular Compression (Indirect): Mild ocular massage can transiently reduce intralesional pressure in minor hemorrhages (anecdotal) Retina Today.

15. Scleral Buckling: Rarely used for tractional detachments secondary to fibrotic proliferation Retina Today.

16. Vitrectomy with Silicone Oil Tamponade: For complex traction and hemorrhage, silicone oil stabilizes the retina postoperatively Retina Today.

17. Epiretinal Fibrosis Release: Combined with vitrectomy to relieve traction on macula Retina Today.

18. Radiation Plaque Removal Surgery: After adequate dose delivery, plaques are removed to minimize long-term radiation exposure Retina Today.

19. Prophylactic Treatment of Fellow Eye: In bilateral/familial cases, early intervention on minimal lesions may prevent growth Retina Today.

20. Multidisciplinary Surveillance: Coordination with neurology for CCM monitoring ensures systemic vascular health Retina TodayScienceDirect.

---

Drug Treatments

1. Oral Propranolol (β-blocker): 1–2 mg/kg/day in divided doses; vasoconstriction and anti-angiogenic effects may reduce lesion size (off-label; anecdotal) Retina TodayNew England Journal of Medicine.

2. Oral Acetazolamide (Carbonic Anhydrase Inhibitor): 250 mg twice daily; reduces intraocular fluid production, potentially diminishing retinal edema Retina Today.

3. Oral Prednisone (Systemic Corticosteroid): 0.5–1 mg/kg/day taper; anti-inflammatory to control secondary proliferative gliosis Retina Today.

4. Intravitreal Bevacizumab (Anti-VEGF): 1.25 mg injection; off-label for reducing macular edema, limited effect on tumor regression Retina Today.

5. Intravitreal Ranibizumab: 0.5 mg monthly; reduces subretinal fluid when exudation occurs (PCV trials extrapolated) PMC.

6. Intravitreal Aflibercept: 2 mg monthly; similar anti-VEGF properties, useful for macular complications PMC.

7. Intravitreal Triamcinolone Acetonide: 4 mg injection; corticosteroid to control inflammation and edema PMC.

8. Sirolimus (mTOR Inhibitor): 1 mg daily; anti-angiogenic and immunosuppressive, theoretical use from systemic hemangioma data PMC.

9. Thalidomide (Immunomodulator): 50–100 mg nightly; anti-angiogenic, severe teratogenic risks limit use Wikipedia.

10. Interferon-α (Immunotherapy): 3 million IU subcutaneously three times/week; anti-angiogenic in other hemangiomas PMC.

---

Dietary Molecular & Herbal Supplements

(Evidence for cavernous hemangioma is lacking; these are extrapolated from retinal vascular and neuroprotective studies.)

1. Curcumin: 500 mg orally twice daily; anti-inflammatory, antioxidant, downregulates VEGF expression PMC+1.

2. Lutein: 10 mg daily; carotenoid antioxidant, supports retinal pigment epithelium integrity FrontiersWikipedia.

3. Zeaxanthin: 2 mg daily; complements lutein, filters blue light, antioxidant Frontiers.

4. Omega-3 Fatty Acids (EPA/DHA): 1 g daily; anti-inflammatory, supports vascular health Frontiers.

5. Vitamin C: 500 mg daily; antioxidant, collagen synthesis for vessel stability Frontiers.

6. Vitamin E: 400 IU daily; lipid-soluble antioxidant protecting membranes Frontiers.

7. Zinc: 80 mg daily; cofactor for antioxidant enzymes Frontiers.

8. Copper: 2 mg daily; works with zinc in superoxide dismutase Frontiers.

9. Bilberry Anthocyanins: 80 mg twice daily; enhance antioxidant defenses, reduce retinal oxidative stress PMC.

10. Ginkgo Biloba Extract: 120 mg daily; improves microcirculation, antioxidant effects PMC.

11. Resveratrol: 150 mg twice daily; anti-angiogenic by binding VEGF, neuroprotective PMCMDPI.

12. N-Acetylcysteine (NAC): 600 mg twice daily; replenishes glutathione, reduces ROS in retina PLOS.

13. Green Tea Catechins (EGCG): 300 mg daily; antioxidant, upregulates retinal SOD/GPX PMC.

14. Coenzyme Q10: 100 mg daily; mitochondrial antioxidant, supports cellular energy IOVS.

15. Astaxanthin: 4 mg daily; potent carotenoid antioxidant, crosses blood–retinal barrier Frontiers.

---

Regenerative & Stem-Cell-Based Therapies (Experimental)

1. Intravitreal Autologous Bone Marrow Mononuclear Cells: ~1×10⁶ CD34⁺ cells; release trophic factors, modulate angiogenesis PMC.

2. Intravitreal Mesenchymal Stem Cell-Derived Exosomes: ~50 µg protein; anti-inflammatory and neuroprotective cargo ScienceDirect.

3. Autologous CD34⁺ Cell Infusion (Intravenous): 1×10⁶ cells/kg; mobilizes endothelial progenitors, supports vessel repair Ophthalmology Science.

4. Recombinant Human Erythropoietin: 33,000 IU subcutaneously weekly; neurotrophic and angiogenic modulation in retinal ischemia Nature.

5. Intravitreal Ciliary Neurotrophic Factor (CNTF) Implant: 100 µg sustained-release; supports neuronal survival Nature.

6. Human Embryonic Stem Cell-Derived RPE Patch (Subretinal): implant delivering RPE cells; promotes retinal repair in degenerative conditions Lippincott Journals.

---

Surgeries

1. Pars Plana Vitrectomy: Clears non-resolving vitreous hemorrhage, restores vision Retina Today.

2. Epiretinal Membrane Peeling: Removes fibrous tissue over macula, improves visual acuity Retina Today.

3. Internal Tumor Resection (Pars Plana Route): Direct excision for large, vision-threatening lesions Retina Today.

4. Plaque Brachytherapy Placement/Removal: Episcleral plaque insertion for localized radiation; removal after dose delivery Retina Today.

5. Subretinal Fluid Drainage & Retinal Reattachment: Surgical drainage to flatten retina in exudative detachment Retina Today.

---

Prevention Strategies

1. Regular Eye Examinations: Early detection prevents complications Retina Today.

2. Family Screening: Genetic counseling and screening in bilateral/familial cases ScienceDirect.

3. Control Systemic Hypertension: Reduces vascular stress on retinal vessels Retina Today.

4. Avoidance of Ocular Trauma: Protects against hemorrhage in vulnerable lesions Retina Today.

5. Minimize Valsalva Maneuvers: Prevents sudden increases in venous pressure Retina Today.

6. Smoking Cessation: Improves microvascular health Retina Today.

7. Maintain Cardiovascular Fitness: Regular exercise supports vascular integrity Retina Today.

8. Healthy Diet: Rich in antioxidants to protect retinal vessels Frontiers.

9. Avoidance of Prolonged High-Altitude Exposure: Reduces hypoxia-induced vascular stress Retina Today.

10. Ocular Sun Protection: UV-blocking sunglasses to limit oxidative damage Retina Today.

---

When to See a Doctor

• Sudden onset of floaters or flashes

• New or worsening blurred vision

• Persistent vitreous clouding

• Signs of vitreous hemorrhage (dark red haze)

• Any eye pain or discomfort
  Seek immediate evaluation to rule out complications like hemorrhage or tractional detachment Retina Today.

---

Dietary Do’s & Don’ts

Do eat leafy greens (spinach, kale), oily fish (salmon, mackerel), colorful fruits (berries), nuts (walnuts), and whole grains—rich in antioxidants and omega-3s Frontiers.
Don’t eat excessive processed foods, high-glycemic carbs, trans fats, and heavy alcohol—these promote inflammation and vascular damage Frontiers.

---

Frequently Asked Questions (FAQs)

1. What causes a retinal cavernous hemangioma?
   Genetic mutations (CCM1–3) or sporadic vascular malformation during development Retina Today.

2. Is it cancerous?
   No—it’s a benign vascular hamartoma with no malignant potential Retina Today.

3. Can it improve on its own?
   Lesions often remain stable or involute spontaneously via thrombosis Retina Today.

4. Will it cause blindness?
   Rarely—only if complications (hemorrhage, traction) involve the macula Retina Today.

5. How is it diagnosed?
   Fundoscopy, OCT, FA, and ultrasonography confirm typical features Retina Today.

6. Do I need genetic testing?
   Yes for bilateral or familial cases to screen for cerebral cavernomas Retina Today.

7. Can it recur after treatment?
   Rare recurrence if lesion fully sclerosed; ongoing monitoring is essential Retina Today.

8. Are injections needed?
   Only for macular edema; anti-VEGF or steroids manage fluid, not the tumor itself Retina Today.

9. What is the most effective therapy?
   Observation first—intervene with vitrectomy, PDT, or brachytherapy if vision threatened Retina Today.

10. Is there a link to brain lesions?
    Yes—14% have cerebral cavernomas; MRI is advised in all cases Retina TodayScienceDirect.

11. Can I drive with this condition?
    Yes, unless vision is impaired by hemorrhage or macular involvement Retina Today.

12. What follow-up schedule is recommended?
    Every 6–12 months for stable lesions; sooner if symptoms develop Retina Today.

13. Are there lifestyle changes to help?
    Control blood pressure, avoid smoking, maintain healthy diet and exercise Retina TodayFrontiers.

14. Can supplements cure it?
    No cure, but antioxidants may support retinal health; no direct evidence for lesion regression Frontiers.

15. Where can I find support?
    Seek retina specialists and genetic counselors; patient advocacy groups for cavernous malformations offer resources.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 07, 2025.

PDF Document For This Disease Conditions References